

NEUROCRINE BIOSCIENCES INC
Form 8-K
November 27, 2001

=====

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): November 27, 2001

NEUROCRINE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other
jurisdiction of
incorporation)

0-28150
(Commission File Number)

33-0525145
(IRS Employer
Identification Number)

10555 SCIENCE CENTER DRIVE, SAN DIEGO, CA
(Address of principal executive offices)

92121
(Zip Code)

Registrant's telephone number, including area code: (858) 658-7600

N/A

(Former name or former address, if changed since last report.)

=====

This Current Report on Form 8-K is filed by Neurocrine Biosciences, Inc., a Delaware corporation (the "Company"), in connection with the matters described herein.

ITEM 5. OTHER EVENTS

On November 27, 2001, the Company announced the dosing of seven subjects in the initiation of a Phase I clinical trial with the Company's proprietary, orally active, gonadotropin-releasing hormone antagonist. A copy of the Company's press release announcing the initiation of the clinical trial, dated November 27, 2001, is attached hereto as Exhibit 99.1 and incorporated herein by

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 8-K

reference.

ITEM 7. EXHIBITS

(c) Exhibits. The following exhibits are filed herewith:

Exhibit Number -----	Description of Exhibit -----
99.1	Press Release, dated November 27, 2001.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 27, 2001

/s/ Paul W. Hawran

Paul W. Hawran
Executive Vice President
and Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Press Release, dated November 27, 2001.